Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?
about
Atherosclerosis in psoriatic disease: latest evidence and clinical implicationsIs immunity a mechanism contributing to statin-induced diabetes?The influence of innate and adaptive immune responses on atherosclerosisImmunity, atherosclerosis and cardiovascular diseaseCaspase-1-mediated pathway promotes generation of thromboinflammatory microparticles.Linking Chronic Inflammation with Cardiovascular Disease: From Normal Aging to the Metabolic Syndrome.High sensitivity C reactive protein as a prognostic marker in patients with mild to moderate aortic valve stenosis during lipid-lowering treatment: an SEAS substudy.Egg yolks inhibit activation of NF-κB and expression of its target genes in adipocytes after partial delipidation.Dietary Inflammatory Index and Incidence of Cardiovascular Disease in the SUN Cohort.Improving cardiovascular health and metabolic comorbidities in patients with psoriatic arthritisImmune mechanisms in atherosclerosis, especially in diabetes type 2Oxidized Low-Density Lipoprotein (OxLDL)-Treated Dendritic Cells Promote Activation of T Cells in Human Atherosclerotic Plaque and Blood, Which Is Repressed by Statins: microRNA let-7c Is Integral to the Effect.The risk of atrial fibrillation in patients with rheumatoid arthritisRheumatoid arthritis and cardiovascular diseaseThe biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.Targeting inflammation: impact on atherothrombosis.Prediction and management of cardiovascular outcomes in systemic lupus erythematosus.Advances in non-invasive drug delivery for atherosclerotic heart disease.Inflammatory markers and cardiometabolic diseases.Pediatric Loss of Control Eating and High-Sensitivity C-Reactive Protein Concentrations.Cardiometabolic Disorders in Psoriatic Disease.Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV InfectionAnti-atherogenic effects of methotrexate carried by a lipid nanoemulsion that binds to LDL receptors in cholesterol-fed rabbits.The heart matters in diabetes: 10-Year outcomes of peripheral artery disease.Inflammatory Biomarkers of Cardiometabolic Risk in Obese Egyptian Type 2 Diabetics.Linking the sympathetic nervous system to the inflammasome: towards new therapeutics for atherosclerotic cardiovascular disease.Serum levels of pentraxin-3 and other inflammatory biomarkers in migraine: Association with migraine characteristics.Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?Ceramide Remodeling and Risk of Cardiovascular Events and Mortality.
P2860
Q26783501-2AE7E3BB-BEB3-432B-B300-245800FB6D79Q26785561-D80E7386-BB2C-4A7D-920C-7CDD28D8870BQ27000370-DA93A4A6-1261-4D8A-AD74-951A4ADF2BB4Q28688590-735D8BB7-31F6-4DA8-B3D8-D1FF250546A6Q30639688-5B5F77E8-4BFE-455A-9A83-2E331F07EDBBQ33847586-9859AEE5-4DC4-4390-B2B6-D850CA81CDB9Q35065597-057F5C6C-8EBB-449F-83B4-1364F928FC43Q35184881-F1F016DB-43CA-4CBE-BAC8-68A7FE11EE80Q35764565-2B741561-3288-4983-9702-47A56726B826Q36843650-EE2CD8D3-F24C-4667-99B1-5156E907DF62Q37261617-FFE45495-A93C-411A-A149-816E21036F96Q37364489-54451CC4-0E3B-4137-BB42-6E4F63EB5030Q37446317-4B34E4B3-DBC6-444F-BB9E-14AE51DEA218Q38149252-16176F1A-5D7D-4B7C-B397-59724BB7D8B4Q38151675-A119F617-6762-4187-B6F1-19D8F97216F6Q38170328-A99AF33F-3E8C-4B66-82B6-1538BE36269EQ38291820-32CF042C-2D02-4424-87C0-F3E50959F54BQ38317205-3A5052BD-C2E9-493E-AB00-E0F5C20DD9A1Q38535519-7AE194F9-EEDF-49D1-90F3-0737842DA290Q38812419-AE079926-1B4D-4BB7-9DC4-1FD2362D8805Q40069191-75A245AD-D334-462D-ADE1-5D1D4B9E5A2FQ40692524-EA84787D-81AC-4384-945E-087D77E16CBAQ42709233-A6F1C3A3-88F0-4602-94F3-B9F94F6D30E3Q46019677-BA4098BD-615E-407B-9425-BBA260606AB2Q47445962-18BAAC68-2422-48DA-875C-7E3431E6E898Q50094089-E9333DF0-B324-4535-BFE7-74E7BED765D3Q53394696-D9279FCD-B089-453C-974C-87F7E25CF6C3Q54203490-61684DF2-87F4-402A-B7B9-207475608C16Q55431160-72EED9FA-CF90-4436-9618-3302F16881D8
P2860
Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?
@en
Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?
@nl
type
label
Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?
@en
Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?
@nl
prefLabel
Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?
@en
Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?
@nl
P2860
P1476
Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?
@en
P2093
Paul M Ridker
P2860
P2888
P356
10.1007/S11883-012-0295-3
P577
2013-01-01T00:00:00Z